Ruff Shamim 4
4 · REATA PHARMACEUTICALS INC · Filed Aug 1, 2023
Insider Transaction Report
Form 4
Ruff Shamim
Director
Transactions
- Exercise/Conversion
Class A common stock
2023-07-28$92.20/sh+319$29,412→ 15,594 total - Sale
Class A common stock
2023-07-28$164.53/sh−8,235$1,354,887→ 7,359 total - Exercise/Conversion
Stock Option (right to buy)
2023-07-28−319→ 0 totalExercise: $92.20Exp: 2031-04-15→ Class A common stock (319 underlying) - Exercise/Conversion
Class A common stock
2023-07-28$92.20/sh+6,666$614,605→ 15,275 total - Exercise/Conversion
Stock Option (right to buy)
2023-07-28−1,250→ 0 totalExercise: $92.20Exp: 2031-04-15→ Class A common stock (1,250 underlying) - Exercise/Conversion
Class A common stock
2023-07-28$92.20/sh+1,250$115,250→ 8,609 total - Exercise/Conversion
Stock Option (right to buy)
2023-07-28−6,666→ 3,334 totalExercise: $92.20Exp: 2031-04-15→ Class A common stock (6,666 underlying)
Footnotes (5)
- [F1]The exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $164.25 to $164.69. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The options vested on July 15, 2021.
- [F4]The options vest in three equal yearly installments through April 15, 2024, subject to continued service through each vesting date.
- [F5]The options vested on July 15, 2021.